Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 2605628, 8 pages
https://doi.org/10.1155/2017/2605628
Review Article

Current Tissue Molecular Markers in Colorectal Cancer: A Literature Review

1Department of Advanced Biomedical Science, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy
2Department of Public Health, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy

Correspondence should be addressed to Gaia Peluso; moc.liamg@5osulep.aiag

Received 14 April 2017; Revised 18 September 2017; Accepted 3 October 2017; Published 29 October 2017

Academic Editor: Fotios Loupakis

Copyright © 2017 Gaia Peluso et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. R. Marley and H. Nan, “Epidemiology of colorectal cancer,” International Journal of Molecular Epidemiology and Genetics, vol. 7, no. 3, pp. 105–114, 2016. View at Google Scholar
  2. F. A. Haggar and R. P. Boushey, “Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors,” Clinics in Colon and Rectal Surgery, vol. 22, no. 4, pp. 191–197, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Shussman and S. D. Wexner, “Colorectal polyps and polyposis syndromes,” Gastroenterology Report, vol. 2, no. 1, pp. 1–15, 2014. View at Publisher · View at Google Scholar
  4. N. Carlomagno, F. Schonauer, V. Tammaro, A. Di Martino, C. Criscitiello, and M. L. Santangelo, “A multidisciplinary approach to an unusual medical case of locally advanced gastric cancer: a case report,” Journal of Medical Case Reports, vol. 9, p. 13, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Santangelo, A. Esposito, V. Tammaro et al., “What indication, morbidity and mortality for central pancreatectomy in oncological surgery? A systematic review,” International Journal of Surgery, vol. 28, pp. S172–S176, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. V. Das, J. Kalita, and M. Pal, “Predictive and prognostic biomarkers in colorectal cancer: A systematic review of recent advances and challenges,” Biomedicine & Pharmacotherapy, vol. 87, pp. 8–19, 2017. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Santangelo, G. Romano, G. Vescio, F. Bossa, F. Manzo, and M. L. Santangelo, “Functional results of colorectal and coloanal anastomosis with and without pouch Ann Ital Chir,” Review. Italian, vol. 72, no. 4, PMID: 11865697, pp. 443–448, 2001. View at Google Scholar
  8. F. Amersi, M. Agustin, and C. Y. Ko, “Colorectal cancer: Epidemiology, risk factors, and health services,” Clinics in Colon and Rectal Surgery, vol. 18, no. 3, pp. 133–140, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. M. L. Santangelo, C. Grifasi, C. Criscitiello et al., “Bowel obstruction and peritoneal carcinomatosis in the elderly. A systematic review,” Aging Clinical and Experimental Research, vol. 29, no. 1, pp. 73–78, 2017. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Carlomagno, M. L. Santangelo, B. Amato et al., “Total colectomy for cancer: Analysis of factors linked to patients' age,” International Journal of Surgery, vol. 12, no. 2, pp. S135–S139, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. C. S. McArdle and D. J. Hole, “Outcome following surgery for colorectal cancer,” British Medical Bulletin, vol. 64, pp. 119–125, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Botteri, S. Iodice, S. Raimondi, P. Maisonneuve, and A. B. Lowenfels, “Cigarette Smoking and Adenomatous Polyps: a meta-analysis,” Gastroenterology, vol. 134, no. 2, pp. 388–395, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Botteri, S. Iodice, V. Bagnardi, S. Raimondi, A. B. Lowenfels, and P. Maisonneuve, “Smoking and colorectal cancer: a meta-analysis,” The Journal of the American Medical Association, vol. 300, no. 23, pp. 2765–2778, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. M. L. Santangelo, C. Criscitiello, A. Renda et al., “Immunosuppression and multiple primary malignancies in kidney-transplanted patients: a single-institute study,” BioMed Research International, vol. 2015, Article ID 183523, 8 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. S. C. Larsson and A. Wolk, “Meat consumption and risk of colorectal cancer: a meta-analysis of prospective studies,” International Journal of Cancer, vol. 119, no. 11, pp. 2657–2664, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. R. L. Santarelli, F. Pierre, and D. E. Corpet, “Processed meat and colorectal cancer: A review of epidemiologic and experimental evidence,” Nutrition and Cancer, vol. 60, no. 2, pp. 131–144, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. T. J. Key, A. Schatzkin, W. C. Willett, N. E. Allen, E. A. Spencer, and R. C. Travis, “Diet, nutrition and the prevention of cancer,” Public Health Nutrition, vol. 7, no. 1 A, pp. 187–200, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Pöschl and H. K. Seitz, “Alcohol and cancer,” Alcohol & Alcoholism, vol. 39, no. 3, pp. 155–165, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. N. Homann, J. Tillonen, and M. Salaspuro, “Microbially produced acetaldehyde from ethanol may increase the risk of colon cancer via folate deficiency,” International Journal of Cancer, vol. 86, no. 2, pp. 169–173, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. L.-K. Su, B. Vogelstein, and K. W. Kinzler, “Association of the APC tumor suppressor protein with catenins,” Science, vol. 262, no. 5140, pp. 1734–1737, 1993. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Volgstein, The Basis of Human Cancer, 2nd edition.
  22. S. D. Markowitz and M. M. Bertagnolli, “Molecular basis of colorectal cancer,” The New England Journal of Medicine, vol. 361, no. 25, pp. 2404–2460, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Armaghany, J. D. Wilson, Q. Chu, and G. Mills, “Genetic alterations in colorectal cancer,” Gastrointestinal Cancer Research, vol. 5, no. 1, pp. 19–27, 2012. View at Google Scholar · View at Scopus
  24. C. Lengauer, K. W. Kinzler, and B. Vogelstein, “Genetic instability in colorectal cancers,” Nature, vol. 386, no. 6625, pp. 623–627, 1997. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Rajagopalan, A. Bardelli, C. Lengauer, K. W. Kinzler, B. Vogelstein, and V. E. Velculescu, “RAF/RAS oncogenes and mismatch-repair status,” Nature, vol. 418, article 934, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. H. J. Andreyev, A. R. Norman, and D. Cunningham, “Kirsten ras mutations in patients with colorectal cancer: the "RASCAL II" study,” British Journal of Cancer, vol. 85, no. 5, pp. 692–696, 2001. View at Google Scholar
  27. M. J. O'Brien, “Hyperplastic and serrated polyps of the colorectum,” Gastroenterology Clinics of North America, vol. 36, no. 4, pp. 947–968, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Shibata, M. A. Reale, P. Lavin et al., “The DCC protein and prognosis in colorectal cancer,” The New England Journal of Medicine, vol. 335, no. 23, pp. 1727–1732, 1996. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Saito, A. Yamaguchi, T. Goi et al., “Expression of DCC protein in colorectal tumors and its relationship to tumor progression and metastasis,” Oncology, vol. 56, no. 2, pp. 134–141, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Bogaert and H. Prenen, “Molecular genetics of colorectal cancer,” Annals of Gastroenterology, vol. 27, no. 1, pp. 9–14, 2014. View at Google Scholar · View at Scopus
  31. I. M. Hisamuddin and V. W. Yang, “Molecular genetics of colorectal cancer: An overview,” Current Colorectal Cancer Reports, vol. 2, no. 2, pp. 53–59, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. N. Carlomagno, MI. Scarano, S. Gargiulo et al., “Familial colonic polyposis: effect of molecular analysis on the diagnostic-therapeutic approach,” Annali Italiani Di Chirurgia, vol. 72, no. 2, pp. 207–214, 2001. View at Google Scholar
  33. M. I. Scarano, M. De Rosa, L. Panariello et al., “Familial adenomatous polyposis coli: five novel mutations in exon 15 of the adenomatous polyposis coli (APC) gene in Italian patients. Mutations in brief no. 225. Online.,” Human Mutation, vol. 13, no. 3, pp. 256-257, 1999. View at Google Scholar · View at Scopus
  34. M. De Rosa, M. I. Scarano, L. Panariello et al., “Three submicroscopic deletions at the APC locus and their rapid detection by quantitative-PCR analysis,” European Journal of Human Genetics, vol. 7, no. 6, pp. 695–703, 1999. View at Publisher · View at Google Scholar · View at Scopus
  35. N. Carlomagno, M. L. Santangelo, R. Mastromarino, A. Calogero, C. Dodaro, and A. Renda, “Rare multiple primary malignancies among surgical patients—a single surgical unit experience,” Ecancermedicalscience, vol. 8, article 438, 2014. View at Publisher · View at Google Scholar
  36. K. W. Jasperson, T. M. Tuohy, D. W. Neklason, and R. W. Burt, “Hereditary and Familial Colon Cancer,” Gastroenterology, vol. 138, no. 6, pp. 2044–2058, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. H. T. Lynch and A. de la Chapelle, “Hereditary colorectal cancer,” The New England Journal of Medicine, vol. 348, no. 10, pp. 919–932, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. I. Munteanu and B. Mastalier, “Genetics of colorectal cancer,” Journal of Medicine and Life, vol. 7, no. 4, pp. 507–511, 2014. View at Google Scholar
  39. C. G. Solomon and J. M. Inadomi, “Screening for Colorectal Neoplasia,” The New England Journal of Medicine, vol. 376, no. 2, pp. 149–156, 2017. View at Publisher · View at Google Scholar
  40. “Health quality ontario fecal occult blood test for colorectal cancer screening an evidence-based analysis,” Ontario Health Technology Assessment Series, vol. 9, no. 10, pp. 1–40, 2009.
  41. E. J. Kuipers, T. Rösch, and M. Bretthauer, “Colorectal cancer screening - Optimizing current strategies and new directions,” Nature Reviews Clinical Oncology, vol. 10, no. 3, pp. 130–142, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. E. H. Schreuders, E. J. Grobbee, M. C. Spaander, and E. J. Kuipers, “Advances in fecal tests for colorectal cancer screening,” Current Treatment Options in Gastroenterology, vol. 14, no. 1, pp. 152–162, 2016. View at Publisher · View at Google Scholar
  43. S. H. Elsafi, N. I. Alqahtani, N. Y. Zakary, and E. M. Al Zahrani, “The sensitivity, specificity, predictive values, and likelihood ratios of fecal occult blood test for the detection of colorectal cancer in hospital settings,” Clinical and Experimental Gastroenterology, vol. 8, pp. 279–284, 2015. View at Publisher · View at Google Scholar · View at Scopus
  44. J. S. Mandel, T. R. Church, J. H. Bond et al., “The effect of fecal occult-blood screening on the incidence of colorectal cancer,” The New England Journal of Medicine, vol. 343, no. 22, pp. 1603–1607, 2000. View at Publisher · View at Google Scholar · View at Scopus
  45. R. Labianca and B. Merelli, “Screening and diagnosis for colorectal cancer: present and future,” Tumori, vol. 96, no. 6, pp. 889–901, 2010. View at Google Scholar · View at Scopus
  46. S. C. Thigpen and S. A. Geraci, “Cancer Screening 2016,” The American Journal of the Medical Sciences, vol. 352, no. 5, pp. 493–501, 2016. View at Publisher · View at Google Scholar
  47. N. Carlomagno, A. Calogero, and M. Saracco, “Simultaneous quadruple carcinoma of colon case report and literature,” Annali Italiani di Chirurgia, vol. 85, no. 5, pp. 495–500, 2014. View at Google Scholar
  48. H. Brenner, C. Stock, and M. Hoffmeister, “Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality:systematic review and meta-analysis of randomised controlled trials and observational studies,” British Medical Journal, vol. 348, article g2467, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. D. Provenzale, K. Jasperson, D. J. Ahnen et al., Colorectal Cancer Screening, Version 1, CCN Guidelines® Insights, 2015.
  50. M. Kumar and B. D. Cash, “Screening and Surveillance of Colorectal Cancer Using CT Colonography,” Current Treatment Options in Gastroenterology, vol. 15, no. 1, pp. 168–183, 2017. View at Publisher · View at Google Scholar
  51. G. Romano, L. Esercizio, M. Santangelo, G. Vallone, and M. L. Santangelo, “Impact of computed tomography vs. intrarectal ultrasound on the diagnosis, resectability, and prognosis of locally recurrent rectal cancer,” Diseases of the Colon & Rectum, vol. 36, no. 3, pp. 261–265, 1993. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Berretta, L. Alessandrini, C. De Divitiis et al., “Serum and tissue markers in colorectal cancer: State of art,” Critical Review in Oncology/Hematology, vol. 111, pp. 103–116, 2017. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Kalia, “Personalized oncology: Recent advances and future challenges,” Metabolism - Clinical and Experimental, vol. 62, no. 1, pp. S11–S14, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. M. J. Duffy, N. O'Donovan, and J. Crown, “Use of molecular markers for predicting therapy response in cancer patients,” Cancer Treatment Reviews, vol. 37, no. 2, pp. 151–159, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. R. V. Iaffaioli, G. Facchini, A. Tortoriello et al., “Stop Flow in abdominal and pelvic cancer relapses,” Frontiers in Bioscience, vol. 11, no. 2, pp. 1284–1288, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. E. Strocchi, R. V. Iaffaioli, G. Facchini et al., “Stop-flow technique for loco-regional delivery of high dose chemotherapy in the treatment of advanced pelvic cancers,” European Journal of Surgical Oncology, vol. 30, no. 6, pp. 663–670, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. C. L. Sawyers, “The cancer biomarker problem,” Nature, vol. 452, no. 7187, pp. 548–552, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. H. F. A. Vasen, J.-P. Mecklin, P. M. Khan, and H. T. Lynch, “The international collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC),” Diseases of the Colon & Rectum, vol. 34, no. 5, pp. 424-425, 1991. View at Publisher · View at Google Scholar · View at Scopus
  59. A. Mahasneh, F. Al-Shaheri, and E. Jamal, “Molecular biomarkers for an early diagnosis, effective treatment and prognosis of colorectal cancer: Current updates,” Experimental and Molecular Pathology, vol. 102, no. 3, pp. 475–483, 2017. View at Publisher · View at Google Scholar
  60. A. G. Renehan, J. Jones, C. S. Potten, S. M. Shalet, and S. T. O'Dwyer, “Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer,” British Journal of Cancer, vol. 83, no. 10, pp. 1344–1350, 2000. View at Publisher · View at Google Scholar · View at Scopus
  61. J.-M. Liou, C.-T. Shun, J.-T. Liang et al., “Plasma insulin-like growth factor-binding protein-2 levels as diagnostic and prognostic biomarker of colorectal cancer,” The Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 4, pp. 1717–1725, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. C. Piñol-Felis, T. Fernández-Marcelo, J. Viñas-Salas, and C. Valls-Bautista, “Telomeres and telomerase in the clinical management of colorectal cancer,” Clinical and Translational Oncology, vol. 19, no. 4, pp. 399–408, 2017. View at Publisher · View at Google Scholar · View at Scopus
  63. T. Fernández-Marcelo, A. Sánchez-Pernaute, I. Pascua et al., “Clinical relevance of telomere status and telomerase activity in colorectal cancer,” PLoS ONE, vol. 11, no. 2, article e0149626, 2016. View at Publisher · View at Google Scholar · View at Scopus
  64. H. R. Hathurusinghe, K. S. Goonetilleke, and A. K. Siriwardena, “Current status of tumor M2 pyruvate kinase (tumor M2-PK) as a biomarker of gastrointestinal malignancy,” Annals of Surgical Oncology, vol. 14, no. 10, pp. 2714–2720, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. D. K. Dhar, S. W. M. Olde Damink, J. H. Brindley et al., “Pyruvate kinase M2 is a novel diagnostic marker and predicts tumor progression in human biliary tract cancer,” Cancer, vol. 119, no. 3, pp. 575–585, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. A. D. Roth, S. Tejpar, M. Delorenzi et al., “Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial,” Journal of Clinical Oncology, vol. 28, no. 3, pp. 466–474, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Gonzalez-Pons and M. Cruz-Correa, “Colorectal cancer biomarkers: where are we now?” BioMed Research International, vol. 2015, Article ID 149014, 14 pages, 2015. View at Publisher · View at Google Scholar
  68. C. S. Karapetis, S. Khambata-Ford, D. J. Jonker et al., “K-ras mutations and benefit from cetuximab in advanced colorectal cancer,” The New England Journal of Medicine, vol. 359, pp. 1757–1765, 2008. View at Google Scholar
  69. D. D. Won, J. I. Lee, I. K. Lee, S. Oh, E. S. Jung, and S. H. Lee, “The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients,” BMC Cancer, vol. 17, no. 1, 2017. View at Publisher · View at Google Scholar
  70. M. Tanaka, K. Omura, Y. Watanabe, Y. Oda, and I. Nakanishi, “Prognostic factors of colorectal cancer: K‐ras mutation, overexpression of the p53 protein, and cell proliferative activity,” Journal of Surgical Oncology, vol. 57, no. 1, pp. 57–64, 1994. View at Publisher · View at Google Scholar · View at Scopus
  71. B. R. Dix, P. Robbins, R. Soong, D. Jenner, A. K. House, and B. J. Iacopetta, “The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short‐term prognostic indicators of survival,” International Journal of Cancer, vol. 59, no. 6, pp. 747–751, 1994. View at Publisher · View at Google Scholar · View at Scopus
  72. G. Hutchins, K. Southward, and K. Handley, “Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer,” Journal of Clinical Oncology, vol. 29, no. 10, pp. 1261–1270, 2011. View at Publisher · View at Google Scholar
  73. C. W. Toon, A. Chou, K. Desilva et al., “BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer,” Modern Pathology, vol. 27, no. 5, pp. 644–650, 2014. View at Publisher · View at Google Scholar · View at Scopus
  74. C. W. Toon, M. D. Walsh, A. Chou et al., “BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for lynch syndrome,” The American Journal of Surgical Pathology, vol. 37, no. 10, pp. 1592–1602, 2013. View at Publisher · View at Google Scholar · View at Scopus
  75. F. Galuppini, G. Pennelli, F. Loupakis et al., “BRAF p.V600E-specific immunohistochemical assessment in colorectal cancer endoscopy biopsies is consistent with the mutational profiling,” Histopathology, 2017. View at Publisher · View at Google Scholar
  76. D. Roock, B. Claes, D. Bernasconi et al., “Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis,” Lancet Oncology, vol. 11, no. 8, pp. 753–762, 2010. View at Google Scholar
  77. H.-Y. Luo and R.-H. Xu, “Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer,” World Journal of Gastroenterology, vol. 20, no. 14, pp. 3858–3874, 2014. View at Publisher · View at Google Scholar · View at Scopus
  78. M. Jhawer, S. Goel, A. J. Wilson et al., “PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab,” Cancer Research, vol. 68, no. 6, pp. 1953–1961, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. E. Razis, G. Pentheroudakis, G. Rigakos et al., “EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab,” Journal of Cancer Research and Clinical Oncology, vol. 140, no. 5, pp. 737–748, 2014. View at Publisher · View at Google Scholar · View at Scopus
  80. Y. Shirota, J. Stoehlmacher, J. Brabender et al., “ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy,” Journal of Clinical Oncology, vol. 19, no. 23, pp. 4298–4304, 2001. View at Publisher · View at Google Scholar · View at Scopus
  81. P. D. Leiphrakpam, A. Rajput, M. Mathiesen et al., “Ezrin expression and cell survival regulation in colorectal cancer,” Cellular Signalling, vol. 26, no. 5, pp. 868–879, 2014. View at Publisher · View at Google Scholar · View at Scopus
  82. M. Patara, E. M. M. Santos, R. De Almeida Coudry, F. A. Soares, F. O. Ferreira, and B. M. Rossi, “Ezrin expression as a prognostic marker in colorectal adenocarcinoma,” Pathology & Oncology Research, vol. 17, no. 4, pp. 827–833, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. G. Bulut, S.-H. Hong, K. Chen et al., “Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells,” Oncogene, vol. 31, no. 3, pp. 269–281, 2012. View at Publisher · View at Google Scholar · View at Scopus
  84. A. R. Clarke, “Studying the consequences of immediate loss of gene function in the intestine: APC,” Biochemical Society Transactions, vol. 33, no. 4, pp. 665-666, 2005. View at Publisher · View at Google Scholar · View at Scopus
  85. P. Aghagolzadeh and R. Radpour, “New trends in molecular and cellular biomarker discovery for colorectal cancer,” World Journal of Gastroenterology, vol. 22, no. 25, pp. 5678–5693, 2016. View at Publisher · View at Google Scholar · View at Scopus
  86. T.-H. Chen, S.-W. Chang, C.-C. Huang et al., “The prognostic significance of APC gene mutation and miR-21 expression in advanced-stage colorectal cancer,” Colorectal Disease, vol. 15, no. 11, pp. 1367–1374, 2013. View at Publisher · View at Google Scholar · View at Scopus
  87. R. Hamelin, P. Laurent-Puig, S. Olschwang et al., “Association of p53 mutations with short survival in colorectal cancer,” Gastroenterology, vol. 106, no. 1, pp. 42–48, 1994. View at Publisher · View at Google Scholar · View at Scopus
  88. U. Kressner, M. Inganäs, S. Byding et al., “Prognostic value of p53 genetic changes in colorectal cancer,” Journal of Clinical Oncology, vol. 17, no. 2, pp. 593–599, 1999. View at Publisher · View at Google Scholar · View at Scopus
  89. G. S. Falchook and R. Kurzrock, “VEGF and dual-EGFR inhibition in colorectal cancer,” Cell Cycle, vol. 14, no. 8, pp. 1129-1130, 2015. View at Publisher · View at Google Scholar · View at Scopus
  90. D. J. Jonker, C. J. O'Callaghan, C. S. Karapetis et al., “Cetuximab for the treatment of colorectal cancer,” The New England Journal of Medicine, vol. 357, no. 20, pp. 2040–2048, 2007. View at Publisher · View at Google Scholar · View at Scopus
  91. D. Vallböhmer and H.-J. Lenz, “Epidermal growth factor receptor as a target for chemotherapy,” Clinical Colorectal Cancer, vol. 5, no. 1, pp. S19–S27, 2005. View at Publisher · View at Google Scholar · View at Scopus
  92. S. Popat and R. S. Houlston, “A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis,” European Journal of Cancer, vol. 41, no. 14, pp. 2060–2070, 2005. View at Publisher · View at Google Scholar · View at Scopus
  93. J. Jen, H. Kim, S. Piantadosi et al., “Allelic loss of chromosome 18q and prognosis in colorectal cancer,” The New England Journal of Medicine, vol. 331, no. 4, pp. 213–221, 1994. View at Publisher · View at Google Scholar · View at Scopus
  94. Y. Du, X. Zhou, Z. Huang et al., “Meta-analysis of the prognostic value of Smad4 immunohistochemistry in various cancers,” PLoS ONE, vol. 9, no. 10, article e110182, 2014. View at Publisher · View at Google Scholar · View at Scopus
  95. P. W. Voorneveld, R. J. Jacobs, L. L. Kodach, and J. C. H. Hardwick, “A meta-analysis of SMAD4 immunohistochemistry as a prognostic marker in colorectal cancer,” Translational Oncology, vol. 8, no. 1, pp. 18–24, 2015. View at Publisher · View at Google Scholar · View at Scopus
  96. N. D. Sigglekow, L. Pangon, T. Brummer et al., “Mutated in colorectal cancer protein modulates the NFκB pathway,” Anticancer Reseach, vol. 32, no. 1, pp. 73–79, 2012. View at Google Scholar · View at Scopus
  97. Y. Wang, Y. Cao, X. Huang et al., “Allele-specific expression of mutated in colorectal cancer (MCC) gene and alternative susceptibility to colorectal cancer in schizophrenia,” Scientific Reports, vol. 6, article 26688, 2016. View at Publisher · View at Google Scholar · View at Scopus
  98. D. Li, D. Yan, H. Tang et al., “IMP3 Is a novel prognostic marker that correlates with colon cancer progression and pathogenesis,” Annals of Surgical Oncology, vol. 16, no. 12, pp. 3499–3506, 2009. View at Publisher · View at Google Scholar · View at Scopus
  99. H. Takahashi, T. Ishikawa, M. Ishiguro et al., “Prognostic significance of Traf2- and Nck- interacting kinase (TNIK) in colorectal cancer,” BMC Cancer, vol. 15, no. 1, article 794, 2015. View at Publisher · View at Google Scholar · View at Scopus
  100. T. Masuda, T. Ishikawa, K. Mogushi et al., “Overexpression of the S100A2 protein as a prognostic marker for patients with stage II and III colorectal cancer,” International Journal of Oncology, vol. 48, no. 3, pp. 975–982, 2016. View at Publisher · View at Google Scholar · View at Scopus